profit from every $100 of sales.
$0$100
Plus Therapeutics
We have no price for Plus Therapeutics since 7 August 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$3.84-0.57% today
-78.0% since Oct 10, 25
1-year low $2.921-year high $18.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Plus Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$22.4 million of profit last year.
SalesProfit
Plus Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Plus Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Plus Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -20 | -13 | -15 | -15 | |
| -19 | -12 | -8 | -18 | |
| -20 | -13 | -13 | -22 | |
| -288.75 | -106.00 | -58.50 | -7.25 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 24 | 11 | 7 | 16 |
| Cash | 18 | 9 | 0 | 4 |
| Total debt | 6 | 4 | 3 | 1 |
| Total liabilities | 17 | 13 | 16 | 12 |
| 6 | -1 | -9 | 4 | |
| 0 | 0 | 0 | 3 | |
| -127.8% | -360.3% | – | -307.9% | |
| -314.6% | 987.8% | 145.0% | -560.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -13 | -11 | -21 | |
| 1 | 0 | 1 | 0 | |
| -14 | -13 | -11 | -21 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | 0 | |
| 1 | 1 | 1 | 2 |
Valuation
- –
- –
- –
- 4.4×
- 5.1×
- –
- –
- -78.2%
- -84.0%
- 0.0%
Profitability
- 91.5%
- -293.5%
- -429.4%
- -284.9%
- -317.6%
- -188.7%
- 774.8%
- -137.1%
- -381.4%
- 160.7%
Growth
- –
- –
- −94.8%
- –
- +1,663.3%
Financial health
- 0.5×
- 0.21
- 5.0%
- -4.1×
- 1.23
- 1.23
- 0.32
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 987
What analysts expect
- Average price target
- $25.00
- Range
- $25.00 – $25.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -1.05 | -0.85 | −23.8% |
| Mar 12, 2026 | -0.83 | -0.80 | −4.2% |
| Oct 30, 2025 | -0.04 | -0.02 | −100.0% |
| Aug 14, 2025 | -0.01 | -0.09 | +88.9% |
| May 30, 2025 | -0.56 | -0.25 | −125.7% |
| Mar 27, 2025 | -0.67 | -0.51 | −31.4% |
| Nov 14, 2024 | -0.37 | -0.56 | +34.2% |
| Aug 14, 2024 | -0.71 | -0.53 | −34.0% |
News
Starwood signals board review of dividend policy while targeting $800m-plus of 2026 legacy asset resolutionsSeeking Alpha · Nov 6, 2026ePlus Inc (PLUS) (Q2 2027) Earnings Call Highlights: Record $1 Billion in Gross Billings and ...Yahoo Finance · Nov 6, 2026Apollo launches European credit platform with €10B-plus lending capacitySeeking Alpha · Nov 2, 2026GE & GM Earnings, Plus Deals, Deals, DealsYahoo Finance · Nov 1, 2026Here's What the S&P 500 Did the Last 2 Times Its Earnings Grew 25%-Plus for 3 Straight QuartersYahoo Finance · Oct 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
26No pass
Philip Fisher
54No pass
Peter Lynch
49No pass
Joel Greenblatt
2No pass
Charlie Munger
56No pass
Terry Smith
51No pass
Questions about Plus Therapeutics
Is Plus Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Plus Therapeutics AI analysis
What does Plus Therapeutics do?
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. It is in Biotechnology.
Does Plus Therapeutics pay a dividend?
No. Plus Therapeutics does not pay a dividend at the moment.
Is Plus Therapeutics stock halal?
Yes. Plus Therapeutics passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
Who are Plus Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Plus Therapeutics's.
Prices: daily closes to Aug 7, 2026. Fundamentals: company reports via invest-like data.